{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"30.4","value":"40.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Blood plasma cells: CR/CRi"},{"categories":[{"measurements":[{"comment":"SD cannot be calculated for a single participant.","groupId":"OG000","spread":"NA","value":"44.0"},{"comment":"SD cannot be calculated for a single participant.","groupId":"OG001","spread":"NA","value":"55.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Blood plasma cells: Non CR/CRi;"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.9","value":"55.6"},{"groupId":"OG001","spread":"2.1","value":"66.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Blood NK cells: CR/CRi"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.5","value":"61.3"},{"comment":"SD cannot be calculated for a single participant.","groupId":"OG001","spread":"NA","value":"70.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Blood NK cells: Non CR/CRi"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"description":"Blood samples were collected to assess CD38 receptor occupancy as a pharmacodynamics marker. It was assessed across complete responders and non-complete responders. Multicolor flow cytometry assay was validated for CD38 receptor occupancy (CD38RO) quantification, based on the use of two murine monoclonal antibodies (MAbs), one competing with SAR650984 to determine the number of free CD38 receptors (MAb1) and one recognizing a different binding epitope on CD38 to measure the total number of receptors (MAb2) at the cell surface of the cancer cells. Cells were tagged with either MAb1 (Tube #1) or MAb2 (Tube #2). The percentage RO was calculated using the following equation: % CD38RO = \\[(sABC MAb2 - sABC MAb1)/sABC MAb2\\] X 100.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with B-ALL received isatuximab 20 mg/kg IV infusion QW for 4 weeks during the induction period (i.e., on Days 1, 8, 15, and 22) and Q2W during the consolidation period (i.e., on Days 29, 43, and 57. Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG000","title":"B-cell Acute Lymphoblastic Leukemia (B-ALL)"},{"description":"Participants with T-ALL received isatuximab 20 mg/kg IV infusion QW for 4 weeks during the induction period (i.e., on Days 1, 8, 15, and 22) and Q2W during the consolidation period (i.e., on Days 29, 43, and 57. Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG001","title":"T-cell Acute Lymphoblastic Leukemia (T-ALL)"},{"description":"Participants with AML received isatuximab 20 mg/kg IV infusion on Days 1, 8, and 15 of each Cycle (up to 2 treatment cycles, each cycle 28 days). Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG002","title":"Acute Myeloid Leukemia (AML)"}],"paramType":"MEAN","populationDescription":"The evaluable population consisted of evaluable participants from the AT population who received at least 1 full dose of isatuximab in Cycle 1 and who had at least 1 valid response value that was evaluable. Only those participants with data available at specified timepoints were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 15","title":"CD38 Receptor Occupancy","type":"SECONDARY","unitOfMeasure":"percent receptor occupancy"}